Leukemia

Quizartinib Significantly Improves Survival Over Chemotherapy in Patients with Relapsed/Refractory AML and FLT3-ITD Mutation

New results from the phase 3 QuANTUM-R trial showed that quizartinib, an oral, selective FLT3 inhibitor, significantly extended overall survival compared with chemotherapy in patients with relapsed/refractory acute myeloid leukemia (AML) and the FLT3-ITD mutation.

Kymriah (Tisagenlecleucel) for Young Patients with Acute Lymphoblastic Leukemia: First FDA-Approved Gene Therapy

Loretta Fala, Medical Writer

Acute lymphoblastic leukemia (ALL) is a cancer of the blood and bone marrow that affects the white blood cells (lymphocytes). In 2017, 5970 new patients were estimated to be diagnosed with ALL and 1440 individuals to die from this disease. ALL is diagnosed most often in children, adolescents, and young adults, with a median age of 15 years at diagnosis.

Vyxeos (Daunorubicin and Cytarabine) Liposomal Combination First Treatment Approved for Patients with High-Risk Acute Myeloid Leukemia

Lisa A. Raedler, PhD, RPh, Medical Writer

Acute myeloid leukemia (AML) is a rare but deadly cancer. Approximately 21,400 new cases of AML were diagnosed in 2017 in the United States, and nearly 10,600 people died from the disease. Approximately 60% to 70% of adults with AML respond to initial treatment with cytotoxic chemotherapy. However, the 5-year survival rate for patients with AML remains poor at approximately 27%.

Targeting FMS-Like Tyrosine Kinase 3 in the Management of Patients with FLT3-Positive Acute Myeloid Leukemia

Meg Barbor, MPH

At the 2018 Hematology/Oncology Pharmacy Association Annual Conference, Dr Seddon provided attendees with an overview of FLT3-mutated AML, including currently available treatments, mechanisms of resistance, and future directions.

ASH Recaps “Phenomenal” Year for Acute Myeloid Leukemia Drug Approvals

Chase Doyle

In April 2017, midostaurin (Rydapt) was approved for the treatment of adults with newly diagnosed FLT3-positive AML in combination with standard intensive induction consolidation chemotherapy.

New BTK Inhibitor Leads to Durable Responses in Relapsed or Refractory Chronic Lymphocytic Leukemia

Charles Bankhead

Acalabrutinib received FDA approval on October 31, 2017, for patients with mantle-cell lymphoma but not for patients with CLL. It is only the second BTK inhibitor to receive approval by the FDA.

Venetoclax plus Rituximab New Chemotherapy-Free Option for Chronic Lymphocytic Leukemia

Phoebe Starr

Findings from an interim analysis of the phase 3 MURANO study show venetoclax plus rituximab achieved superior progression-free survival and overall survival compared with standard-of-care bendamustine plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.

Successful Treatment of Chronic Myeloid Leukemia with Low-Dose Nilotinib

Eric Haigh, BS; Kamran Darabi, MD

To our knowledge, cases of successful treatment of chronic myeloid leukemia (CML) with low-dose nilotinib (Tasigna) have not been reported. The following case represents our experience with a patient with CML who achieved good response to nilotinib therapy.

Page 5 of 5
Results 41 - 48 of 48

Leukemia

I'd like to receive: